Acute insulin response and β-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks

Diabetes Care

Volumn 30, Issue 1, 2007, Pages 157-158

  Hardy, Thomas A ^a   Meyers, Adam L ^a   Yu, Jun ^b   Shankar, Sudha S ^c   Steinberg, Helmut O ^c   Porksen, Niels K ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MedFocus   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; OLANZAPINE; PLACEBO; RISPERIDONE;

AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG DOSE ESCALATION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INSULIN SENSITIVITY; NORMAL HUMAN;

BENZODIAZEPINES; BLOOD GLUCOSE; C-PEPTIDE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; REFERENCE VALUES; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS;

EID: 33845992198     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1063     Document Type: Article

References (8)

1. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M, Bergman RN: Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54:862-871, 2005
2. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, Beasley CM, Dananberg J: Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87:2918-2923, 2002
3. Bergman RN, Ader M, Huecking K, Van Citters G: Accurate assessment of β-cell function: the hyperbolic correction. Diabetes 51 (Suppl. 1):S212-S220, 2002
4. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
5. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495, 2004
6. Mittelman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-Wessler M, Bergman RN: Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β-cell response. Diabetes 49:2116-2125, 2000
7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27:596-601, 2004
8. Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry RR, Dananberg J: Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 88:5875-5880, 2003